全文获取类型
收费全文 | 626篇 |
免费 | 31篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 33篇 |
妇产科学 | 7篇 |
基础医学 | 70篇 |
口腔科学 | 18篇 |
临床医学 | 83篇 |
内科学 | 117篇 |
皮肤病学 | 69篇 |
神经病学 | 13篇 |
特种医学 | 126篇 |
外科学 | 25篇 |
综合类 | 22篇 |
预防医学 | 23篇 |
眼科学 | 4篇 |
药学 | 15篇 |
1篇 | |
肿瘤学 | 33篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 2篇 |
2020年 | 5篇 |
2019年 | 6篇 |
2018年 | 13篇 |
2017年 | 4篇 |
2016年 | 9篇 |
2015年 | 14篇 |
2014年 | 16篇 |
2013年 | 21篇 |
2012年 | 11篇 |
2011年 | 17篇 |
2010年 | 29篇 |
2009年 | 29篇 |
2008年 | 15篇 |
2007年 | 23篇 |
2006年 | 17篇 |
2005年 | 15篇 |
2004年 | 10篇 |
2003年 | 5篇 |
2002年 | 8篇 |
2001年 | 6篇 |
2000年 | 4篇 |
1999年 | 6篇 |
1998年 | 37篇 |
1997年 | 46篇 |
1996年 | 40篇 |
1995年 | 21篇 |
1994年 | 30篇 |
1993年 | 22篇 |
1992年 | 10篇 |
1991年 | 10篇 |
1990年 | 13篇 |
1989年 | 25篇 |
1988年 | 21篇 |
1987年 | 10篇 |
1986年 | 8篇 |
1985年 | 8篇 |
1984年 | 14篇 |
1983年 | 14篇 |
1982年 | 12篇 |
1981年 | 11篇 |
1980年 | 7篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1976年 | 4篇 |
1973年 | 1篇 |
1971年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有662条查询结果,搜索用时 0 毫秒
161.
Bluman EM; Schnier GS; Avalos BR; Strout MP; Sultan H; Jacobson FW; Williams DE; Carson WE; Caligiuri MA 《Blood》1996,88(10):3887-3893
162.
163.
Abstract Autonomic nervous system abnormalities in airway control may contribute to the symptoms of asthma, and even to the pathogenesis of bronchial hyperresponsiveness (BHR). Partial pulmonary sympathetic denervation by means of bilateral upper dorsal thoracoscopic D2 –D3 sympathicolysis (TS) is an accepted treatment in severe essential hyperhidrosis (EH). The effects of this intervention on BHR are unknown. The objective of this study was to evaluate whether partial pulmonary sympathetic denervation by means of TS has an effect on BHR. Bronchial challenge tests with histamine, enabling the calculation of the provocative dose causing a 20% reduction in FEV1 (PD20 His ) were performed 1 day before, and 6 weeks and 6 months after TS in 35 patients with severe EH. In nine patients (including three patients with a previous history of asthma) with pre-operative BHR (defined as PD20 His < 2 mg), mean PD20 His did not change significantly at 6 weeks, nor at 6 months after TS (0.62 ± 0.33, 0.71 ± 0.42 and 0.93 ± 0.65 mg, respectively) although there was a non-significant trend towards an increase in PD20 His at 6 months. Three of the 26 patients (12%) without pre-operative BHR became hyperresponsive after TS, whereas 1 of the 9 patients with pre-operative BHR lost hyperresponsiveness. No patient developed asthma symptoms after TS. Upper dorsal thoracoscopic D2 –D3 sympathicolysis performed for the treatment of EH has no significant effects on mean PD20 His and individual loss (11%) or development (12%) of BHR occurs only in a minority of patients. 相似文献
164.
Carlos Antonio Negrato Renan M Montenegro Jr Rosiane Mattar Lenita Zajdenverg Rossana PV Francisco Belmiro Gonçalves Pereira Mauro Sancovski Maria Regina Torloni Sergio A Dib Celeste E Viggiano Airton Golbert Elaine CD Moisés Maria Isabel Favaro Iracema MP Calderon Sonia Fusaro Valeria DD Piliakas José Petronio L Dias Marilia B Gomes Lois Jovanovic 《Diabetology & metabolic syndrome》2010,2(1):1-14
There is an urgent need to find consensus on screening, diagnosing and treating all degrees of DYSGLYCEMIA that may occur during pregnancies in Brazil, considering that many cases of DYSGLYCEMIA in pregnant women are currently not diagnosed, leading to maternal and fetal complications. For this reason the Brazilian Diabetes Society (SBD) and the Brazilian Federation of Gynecology and Obstetrics Societies (FEBRASGO), got together to introduce this proposal. We present here a joint consensus regarding the standardization of clinical management for pregnant women with any degree of Dysglycemia, on the basis of current information, to improve medical assistance and to avoid related complications of Dysglycemia in pregnancy to the mother and the fetus. This consensus aims to standardize the diagnosis among general practitioners, endocrinologists and obstetricians allowing the dissemination of information in basic health units, public and private services, that are responsible for screening, diagnosing and treating disglycemic pregnant patients. 相似文献
165.
166.
167.
HR Arias H Xing K MacDougall MP Blanton F Soti WR Kem 《British journal of pharmacology》2009,157(2):320-330
Background and purpose
Benzylidene-anabaseines (BAs) are partial agonists of the α7 nicotinic acetylcholine receptor (nAChR) but their mechanism(s) of action are unknown. Our study explores several possibilities, including direct interactions of BAs with the nAChR channel.Experimental approach
Functional and radioligand-binding assays were used to examine the interaction of two BA analogues, 3-(2,4-dimethoxybenzylidene)-anabaseine (DMXBA) and its primary metabolite 3-(4-hydroxy-2-methoxybenzylidene)-anabaseine (4OH-DMXBA) with both agonist and non-competitive antagonist (NCA)-binding sites on muscle-type nAChRs.Key results
Both BAs non-competitively inhibited ACh activation of human fetal muscle nAChRs and sterically inhibited the specific binding of the NCAs [piperidyl-3,4-3H(N)]-(N-(1-(2-thienyl)cyclohexyl)-3,4-piperidine ([3H]TCP) and [3H]dizocilpine to Torpedo nAChRs in the desensitized state. These compounds modulated [3H]tetracaine, [14C]amobarbital and [3H]TCP binding to resting nAChRs by allosteric mechanisms. Both BAs enhanced [3H]TCP binding when the nAChR was initially in the resting but activatable state, suggesting that both compounds desensitized the Torpedo nAChR. Although DMXBA failed to activate human fetal muscle nAChRs, 4OH-DMXBA was found to be a partial agonist. [3H]Nicotine competition-binding experiments confirmed that 4OH-DMXBA has higher affinity than DMXBA for the agonist sites, and that DMXBA is also a competitive antagonist.Conclusions and implications
3-(4-hydroxy-2-methoxybenzylidene)-anabaseine is a partial agonist for human fetal muscle nAChRs, whereas DMXBA only has competitive and NCA activities. The NCA-binding site for BAs overlaps both the phencyclidine-and dizocilpine-binding sites in the desensitized Torpedo nAChR ion channel. The desensitizing property of BAs suggests another possible mode of non-competitive inhibition in addition to direct channel-blocking mechanisms. 相似文献168.
A Masurel‐Paulet J Andrieux P Callier JM Cuisset C Le Caignec M Holder C Thauvin‐Robinet B Doray E Flori MP Alex‐Cordier M Beri O Boute B Delobel A Dieux L Vallee S Jaillard S Odent B Isidor C Beneteau J Vigneron F Bilan B Gilbert‐Dussardier C Dubourg A Labalme C Bidon A Gautier P Pernes JM Pinoit F Huet F Mugneret B Aral P Jonveaux D Sanlaville L Faivre 《Clinical genetics》2010,78(2):149-161
Masurel‐Paulet A, Andrieux J, Callier P, Cuisset JM, Le Caignec C, Holder M, Thauvin‐Robinet C, Doray B, Flori E, Alex‐Cordier MP, Beri M, Boute O, Delobel B, Dieux A, Vallee L, Jaillard S, Odent S, Isidor B, Beneteau C, Vigneron J, Bilan F, Gilbert‐Dussardier B, Dubourg C, Labalme A, Gautier A, Pernes P, Bidon C, Pinoit JM, Huet F, Mugneret F, Aral B, Jonveaux P, Sanlaville D, Faivre L. Delineation of 15q13.3 microdeletions. The increasing use of array‐comparative genomic hybridization (array‐CGH) to identify copy number variations (CNVs) in patients with developmental delay (DD), mental retardation and/or dysmorphic features has allowed the recent recognition of numerous genomic imbalances, including the 15q13.3 microdeletion. Patients with this microdeletion generally present with relatively consistent breakpoints at BP4 and BP5, which include the CHRNA7 gene. About 100 index cases have been reported since the first publication in 2008. This large number of patients ascertained through highly variable samples has been necessary to describe the full phenotypic spectrum of this microdeletion, ranging from mental retardation with dysmorphic features, epilepsy, neuropsychiatric disturbances with or without cognitive impairment to complete absence of anomalies. Here, we describe a collaborative study reporting a new cohort of 12 index patients and 13 relatives carrying a heterozygous BP4–BP5 microdeletion out of a series of 4625 patients screened by array‐CGH for DD. We confirm the clinical expressivity of the disease as well as the incomplete penetrance in seven families. We showed through a review of the literature that males are more likely to be symptomatic. Sequence analysis of CHRNA7 yielded no data to support the unmasking of recessive variants as a cause of phenotypic variability. We also report the first patient carrying a 15q13.3 homozygous microdeletion inherited from both parents. He had severe epileptic encephalopathy with retinopathy, autistic features and choreoathetosis. Besides the classical ~1.5 Mb BP4–BP5 microdeletion, we also describe three index patients and two relatives with a smaller 500 kb microdeletion, including the CHRNA7 gene. 相似文献
169.
S Parodi C Vollono MP Baglietto M Balestri M Di Duca PA Landri I Ceccherini G Ottonello MR Cilio 《Clinical genetics》2010,78(3):289-293
Parodi S, Vollono C, Baglietto MP, Balestri M, Di Duca M, Landri PA, Ceccherini I, Ottonello G, Cilio MR. Congenital central hypoventilation syndrome: genotype–phenotype correlation in parents of affected children carrying a PHOX2B expansion mutation. Congenital Central Hypoventilation Syndrome (CCHS) is a rare genetic disorder. Although most CCHS associated PHOX2B mutations occur de novo, about 10% of the cases are inherited from apparently asymptomatic parents, thus confirming variable expressivity and incomplete penetrance of PHOX2B mutations. Three asymptomatic parents of children affected with CCHS, and found to carry the same PHOX2B expansion mutations as their siblings, were studied by overnight polysomnography and somatic mosaicism analysis. In one case, significant sleep breathing control anomalies were detected, while the other two resulted in normal. In tissue‐specific allele studies, mosaicism with a comparatively low mutant allele proportion was showed in the two unaffected adult carriers. Accurate polysomnography and assessment of the degree of somatic mosaicism should be conducted in asymptomatic carriers of PHOX2B mutations, as they may unmask subclinical but significant anomalies 相似文献